Aeka Biochemicals Profile
Key Indicators
- Authorised Capital ₹ 4.90 M
- Paid Up Capital ₹ 2.70 M
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.40 M
- Revenue Growth -68.73%
- Profit Growth 6.65%
- Ebitda -21.51%
- Net Worth -22.74%
- Total Assets -0.49%
About Aeka Biochemicals
Aeka Biochemicals Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 June 2014 and has a history of Ten years and seven months. Its registered office is in Thiruvananthapuram, Kerala, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.90 M and a paid-up capital of Rs 2.70 M.
The company has closed loans amounting to ₹1.40 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Aardra Mouli, Vivek Ganesh, and Padmaja Potti serve as directors at the Company.
Company Details
-
Location
Thiruvananthapuram, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U51397KL2014PTC036761
-
Company No.
036761
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Jun 2014
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Aeka Biochemicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aardra Mouli
|
Managing Director | 17-Jun-2014 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Vivek Ganesh
|
Director | 16-Nov-2016 | Current |
|
Padmaja Potti
|
Director | 23-Dec-2020 | Current |
Financial Performance of Aeka Biochemicals.
Aeka Biochemicals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 68.73% decrease. The company also saw a slight improvement in profitability, with a 6.65% increase in profit. The company's net worth observed a substantial decline by a decrease of 22.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aeka Biochemicals?
In 2021, Aeka Biochemicals had a promoter holding of 72.22% and a public holding of 27.78%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹1.40 M
Charges Breakdown by Lending Institutions
- Kerala Financial Corporation : 0.14 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Dec 2014 | Kerala Financial Corporation | ₹1.40 M | Satisfied |
How Many Employees Work at Aeka Biochemicals?
Unlock and access historical data on people associated with Aeka Biochemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aeka Biochemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aeka Biochemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
